Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

• Published in: CA: a cancer journal for clinicians Vol. 73; no. 5; pp. 480 - 515
• Main Authors: Huppert, Laura A., Gumusay, Ozge, Idossa, Dame, Rugo, Hope S.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2023
• Subjects: Breast cancer; breast neoplasms; Cancer therapies; Chemotherapy; clinical trials; Cyclin-dependent kinase; Cyclin-dependent kinase 4; Cyclin-dependent kinases; Disease resistance; Endocrine therapy; Epidermal growth factor; ErbB-2 protein; Estrogen receptors; Gene amplification; hormone receptor‐positive; hormone therapy; human epidermal growth factor receptor 2 (HER2)‐negative breast cancer; Kinases; Metastases; Metastasis; Progesterone; Toxicity; human epidermal growth factor receptor 2 (HER2)-negative breast cancer; clinical trials; hormone therapy; hormone receptor-positive; breast neoplasms
• ISSN: 0007-9235; 1542-4863
• DOI: 10.3322/caac.21777

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR‐positive/HER2‐negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late‐stage disease. Combinations with cyclin‐dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody‐drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR‐positive/HER2‐negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR‐positive/HER2‐negative breast cancer, including treatment algorithms based on current data.